Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-14 04:22 | 2025-11-11 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | Officer | OPT+S | $84.70 | 30,000 | $2,540,922 | 40,555 |
| 2025-11-14 02:06 | 2025-11-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Director, Officer | OPT+S | $21.12 | 100,000 | $2,112,450 | 23,400 |
| 2025-11-14 03:01 | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | Officer | OPT+S | $44.88 | 119,524 | $5,363,711 | 19,396 |
| 2025-11-14 02:04 | 2025-11-11 | EWTX | Edgewise Therapeutics, Inc. | Fox Jonathan C | Director | BUY | $18.64 | 10,700 | $199,403 | 23,702 |
| 2025-11-14 02:59 | 2025-11-11 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $7.40 | 16,667 | $123,296 | 1,336,843 |
| 2025-11-14 03:01 | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $45.44 | 200,000 | $9,088,500 | 631,305 |
| 2025-11-14 00:14 | 2025-11-13 | LLY | ELI LILLY & Co | Zakrowski Donald A | Officer | SELL | $1,010.50 | 1,000 | $1,010,500 | 2,840 |
| 2025-11-14 00:08 | 2025-11-11 | AGIO | Agios Pharmaceuticals Inc. | Gheuens Sarah | Officer | OPT+S | $43.78 | 2,454 | $107,436 | 61,727 |
| 2025-11-14 00:13 | 2025-11-10 | PCRX | Pacira BioSciences, Inc. | Cross Shawn | Officer | SELL | $22.09 | 12,060 | $266,405 | 56,250 |
| 2025-11-14 01:27 | 2025-11-11 | MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | Brust Bernd | Director, Officer | BUY | $3.23 | 250,559 | $809,005 | 250,559 |
| 2025-11-14 00:28 | 2025-11-12 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $11.55 | 3,328 | $38,438 | 398,981 |
| 2025-11-14 05:00 | 2025-11-11 | TBPH | Theravance Biopharma, Inc. | BROSHY ERAN | Director | OPT+S | $18.11 | 59,000 | $1,068,248 | 46,204 |
| 2025-11-14 00:41 | 2025-11-11 | PBYI | PUMA BIOTECHNOLOGY, INC. | MILLER MICHAEL PATRICK | Director | SELL | $4.86 | 20,000 | $97,228 | 54,000 |
| 2025-11-14 00:05 | 2025-11-12 | OGN | Organon & Co. | COX CARRIE SMITH | Director, Officer | BUY | $7.67 | 65,400 | $501,755 | 77,869 |
| 2025-11-14 00:32 | 2025-11-11 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $189.68 | 31,226 | $5,922,795 | 83,111 |
| 2025-11-14 00:33 | 2025-11-13 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $464.76 | 11,000 | $5,112,335 | 36,781 |
| 2025-11-14 02:32 | 2025-11-12 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $594.48 | 8,000 | $4,755,854 | 130 |
| 2025-11-14 04:24 | 2025-11-12 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $45.01 | 30,337 | $1,365,393 | 5,240 |
| 2025-11-13 16:52 | 2025-11-12 | CRVO | CervoMed Inc. | Gregoire Sylvie | Director, 10% owner | BUY | $7.35 | 5,553 | $40,815 | 1,467,131 |
| 2025-11-13 16:52 | 2025-11-12 | CRVO | CervoMed Inc. | ELDER WILLIAM ROBERT | Officer | BUY | $7.44 | 3,500 | $26,040 | 9,000 |
| 2025-11-13 16:52 | 2025-11-12 | CRVO | CervoMed Inc. | ALAM JOHN J | Director, Officer, 10% owner | BUY | $7.35 | 5,553 | $40,815 | 1,467,131 |
| 2025-11-13 00:00 | 2025-11-11 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $986.64 | 283,131 | $279,347,690 | 93,411,978 |
| 2025-11-13 00:00 | 2025-11-10 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $972.52 | 16,869 | $16,405,396 | 93,695,109 |
| 2025-11-13 00:24 | 2025-11-07 | EVMN | Evommune, Inc. | Verduyn-van Weegen Felice Isabel | Director, 10% owner | BUY | $16.00 | 1,562,500 | $25,000,000 | 4,929,633 |
| 2025-11-13 00:01 | 2025-11-10 | MRK | Merck & Co., Inc. | Downing Cristal N | Officer | SELL | $87.00 | 7,085 | $616,395 | 0 |
| 2025-11-13 00:25 | 2025-11-07 | EVMN | Evommune, Inc. | LSP 7 Cooperative UA | 10% owner | BUY | $16.00 | 1,562,500 | $25,000,000 | 4,929,633 |
| 2025-11-13 00:30 | 2025-11-07 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $25.09 | 29,004 | $727,676 | 155,334 |
| 2025-11-13 04:34 | 2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | Officer | SELL | $16.10 | 239 | $3,848 | 9,213 |
| 2025-11-13 04:33 | 2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Officer | SELL | $16.16 | 138 | $2,230 | 15,366 |
| 2025-11-13 04:31 | 2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | Officer | SELL | $16.12 | 95 | $1,531 | 15,750 |
| 2025-11-12 14:05 | 2025-11-07 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $8.43 | 10,600 | $89,358 | 5,583,502 |
| 2025-11-13 02:00 | 2025-11-10 | ASRT | Assertio Holdings, Inc. | Stark David Matthew | Director | SELL | $0.76 | 8,959 | $6,806 | 98,541 |
| 2025-11-13 00:45 | 2025-11-07 | LGND | LIGAND PHARMACEUTICALS INC | Gray Nancy Ryan | Director | OPT+S | $205.45 | 6,571 | $1,350,012 | 8,094 |
| 2025-11-13 04:44 | 2025-11-07 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | Officer | SELL | $2.37 | 40,270 | $95,440 | 869,450 |
| 2025-11-12 14:06 | 2025-11-10 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.10 | 120,000 | $11,760 | 5,634,101 |
| 2025-11-13 01:34 | 2025-11-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $17.40 | 6,667 | $116,034 | 269,974 |
| 2025-11-13 00:33 | 2025-11-10 | APVO | Aptevo Therapeutics Inc. | Grant Grady III | Director | BUY | $1.49 | 13,513 | $20,134 | 13,514 |
| 2025-11-13 00:04 | 2025-11-07 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | Officer | OPT+S | $18.97 | 50,291 | $954,066 | 214,232 |
| 2025-11-13 00:30 | 2025-11-07 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Cramer Pamela J. | Officer | OPT+S | $99.00 | 22,866 | $2,263,825 | 20,814 |
| 2025-11-13 03:32 | 2025-11-07 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $1.13 | 213,529 | $241,288 | 5,691,191 |
| 2025-11-13 00:13 | 2025-11-10 | EBS | Emergent BioSolutions Inc. | DeGolyer Donald W | Director | SELL | $10.54 | 17,801 | $187,623 | 119,858 |
| 2025-11-13 00:26 | 2025-11-07 | EVMN | Evommune, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $16.00 | 1,250,000 | $20,000,000 | 784,345 |
| 2025-11-13 04:36 | 2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Director, Officer | SELL | $16.11 | 412 | $6,637 | 67,159 |
| 2025-11-12 17:19 | 2025-10-28 | ANVS | Annovis Bio, Inc. | Maccecchini Maria-Luisa | Director, Officer | BUY | $2.05 | 97,561 | $200,000 | 1,212,020 |
| 2025-11-12 20:38 | 2025-11-10 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $4.10 | 6,500 | $26,650 | 0 |
| 2025-11-12 17:18 | 2025-10-28 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $2.05 | 975,610 | $2,000,001 | 2,455,539 |
| 2025-11-13 00:44 | 2025-11-07 | LGND | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L | Director | OPT+S | $205.45 | 4,179 | $858,576 | 30,724 |
| 2025-11-13 03:49 | 2025-11-07 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $1.13 | 137,041 | $154,856 | 3,650,433 |
| 2025-11-13 03:31 | 2025-11-07 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $1.13 | 213,529 | $241,288 | 5,691,191 |
| 2025-11-13 00:33 | 2025-11-11 | GALT | GALECTIN THERAPEUTICS INC | 10X Fund, L.P. | 10% owner | SELL | $5.25 | 40,000 | $210,000 | 5,832,207 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.